glycolic acid

Glycolic acid, an inhibitor of tyrosinase, suppresses melanin formation and is used in skincare products.

Lenalidomide-Glycolic acid is a conjugate of an E3 ligase ligand and a linker, used in the synthesis of the PROTAC-type FLT3 degrader LWY713.

Glycolic acid, (5-nitrofurfurylidene)hydrazide is a bioactive chemical.

Glycolic acid oxidase inhibitor 1 (compound 2 in table 1) is an inhibitor of glycolate oxidase, which reduces the risk of kidney stone formation. It also inhibits the contraction of guinea pig ileum induced by slow reactive substances (SRS-A) caused by allergic reactions, and has therapeutic potential for the treatment of allergic diseases such as asthma.

Glycolic acid (Standard) is the standard substance of Glycolic acid, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation,and used in skincare products

Diglycolic acid is a PROTAC linker utilized in the synthesis of PROTAC molecules.

Dithiodiglycolic acid (Standard) is a reference standard of Dithiodiglycolic acid intended for quantitative analysis, quality control, and related biochemical research applications.

Phosphoglycolic acid is closely related to photorespiration and central metabolism, impacting the tissue content of 2-phosphoglycerate.

PLGA (poly(lactic-co-glycolic acid)) is be used to fabricate devices for drug delivery and tissue engineering applications.

PLGA (75:25) is a low-toxicity carrier with biocompatibility and biodegradability, designed for the controlled release of active molecules and achieving sustained release within biological systems. Composed of 75% polylactic acid (PLA) and 25% polyglycolic acid (PGA), PLGA (75:25) has been extensively utilized in the research of delivering active molecules, proteins, and various macromolecules such as DNA, RNA, and peptides.

3-Phosphoglyceric acid is a metabolic intermediate in glycolysis and the Calvin cycle, and it is also involved in alveolar macrophage epigenetic regulation.

Calcium Stearate is a potent Alternative to Poly(vinyl alcohol) in Poly-Lactic-co-Glycolic Acid Nanoparticles Synthesis.

LWY713 is a PROTAC-based FLT3 degrader (DC50=0.64 nM) that selectively induces FLT3 degradation through a cereblon and proteasome-dependent mechanism. It inhibits cell proliferation and causes G0/G1 phase arrest and apoptosis (apoptosis) in MV4-11 cells. In MV4-11 xenograft models, LWY713 demonstrates significant in vivo antitumor activity. The E3 ligase ligand and linker consist of Lenalidomide-Glycolic acid, while the target protein ligand's active control is NaproxenGilteritinib.

OP-145, a derivative of the antimicrobial peptide LL-37, is a synthetic antimicrobial peptide showing activity against E. coli, P. aeruginosa, C. albicans, and A. niger, with minimum inhibitory concentrations (MICs) of 2, 3, 6, and 18 µM, respectively. Utilizing poly(lactic-co-glycolic acid) (PLGA) microspheres loaded with OP-145 effectively prevents biofilm formation in a mouse model of bone infection, which is initiated by surgical femoral fracture and subsequent bacterial inoculation at the fracture site.

mPEG-PLGA (22500-26500) is a biodegradable polymer composed of methyl polyethylene glycol (mPEG) and polylactic-co-glycolic acid (PLGA). It is utilized in drug delivery systems.

mPEG-PLGA (21500-26500) is a biodegradable polymer comprised of methyl polyethylene glycol (mPEG) and poly(lactic-co-glycolic acid) (PLGA). This compound is utilized in drug delivery systems.

PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a PLGA-PEG-Mal nanoparticle comprising poly(lactic-co-glycolic acid) and polyethylene glycol blocks. Its molecular weight is 60kDA-3.4kDA, with a composition ratio of lactic acid (LA) to glycolic acid (GA) molecules at 75:25.

PLGA-PEG-MAL (20kDa-5.0kDa, LA:GA ratio 50:50) is a poly(lactic-co-glycolic acid) block copolymer (PLGA-PEG-Mal) nanoparticle. Its molecular weight is 20kDa-5.0kDa, with a lactic acid (LA) to glycolic acid (GA) ratio of 50:50. This ratio influences the degradation rate of the matrix and the re-release rate of proteins.

PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) is a matrix material for delivering anticancer drugs, with a lactic acid to glycolic acid ratio of 1:1. This compound enhances drug bioavailability, potency, water solubility, drug encapsulation efficiency, sustained drug release, and minimizes adverse toxicity.

PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix material for cancer drug delivery, characterized by a lactic acid to glycolic acid ratio of 15:1. This compound enhances drug bioavailability, efficacy, solubility, drug encapsulation efficiency, and sustained release while minimizing adverse toxicity.

Glycolic-2,2-D2 Acid (Standard) is a reference standard of Glycolic-2,2-D2 Acid intended for quantitative analysis, quality control, and related biochemical research applications.